Medacta Group SA (MOVE) AI Stock Analysis

2 Followers

Medacta Group SA

(Six Swiss:MOVE)

Select Model

Rating:65Neutral

Price Target:CHF 114.00▲(3.64% Upside)

Action:reiterated

Date:11/07/26

The score is supported primarily by strong underlying financial performance (growth and profitability with a solid balance sheet) and a constructive earnings-call outlook with guidance reaffirmed. It is held back by weak technical positioning (trading below major moving averages with soft momentum) and a relatively high P/E with only a modest dividend yield, while cash-flow consistency remains a key risk.

Positive Factors

Sustained revenue growth and profitabilityMedacta has more than doubled revenue since 2020 while retaining strong gross, EBITDA, and net margins. This combination indicates meaningful scale, established demand, and the ability to convert growth into profitability, supporting durable earnings potential over the next several quarters.

Negative Factors

Margin pressure from mix, FX, and pricingThe decline in gross margin shows that growth is currently accompanied by pressure from currency, pricing, and business mix. If these factors persist, they could limit operating leverage and make the company's EBITDA improvement targets more dependent on cost control.

Medacta Group SA (MOVE) vs. iShares MSCI Switzerland ETF (EWL)

Market Cap: CHF 2.89B
Dividend Yield: 1.00%
Average Volume (3M): 32.46K
Price to Earnings (P/E): 30.6
Beta (1Y): 0.80
Revenue Growth: 7.51%
EPS Growth: -20.13%
Country: Switzerland
Employees: 2,273
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Specialties

Medacta Group SA Business Overview & Revenue Model

Company Description

Medacta Group S.A. is a worldwide enterprise specializing in the design, production, and distribution of medical devices for both orthopedic and neurosurgical applications. Operating across Europe, North America, the Asia-Pacific region, and numerous...

How the Company Makes Money

Medacta primarily makes money by selling orthopedic and spine implants and the associated single-use and reusable surgical instrumentation used to implant them. Revenue is generated largely through procedure-driven demand: when hospitals and surgical...

Medacta Group SA Earnings Call Summary

Earnings Call Date:Sep 09, 2026(Q2-2026)|% Change Since:-10.28%|Next Earnings Date:Mar 12, 2027

Earnings Call SentimentPositive

The call was broadly positive, supported by almost 10% constant-currency revenue growth, above-market performance across most product categories and regions, confirmed 2026 and midterm guidance, product launches, India approval, and planned U.S. expansion. However, the period also included meaningful margin pressure, lower operating cash flow, negative free cash flow, a slower-than-expected U.S. market, customer attrition, Spanish strikes, and subdued spine growth. Highlights significantly outweighed the lowlights, although management acknowledged that reaching the midpoint of full-year guidance would be difficult.

Positive Updates

Strong First-Half Revenue and EBITDA Performance

Medacta grew almost 10% in constant currency in H1 2026, reaching EUR 368 million of revenue. Adjusted EBITDA was EUR 97 million, with a margin of 27.8% in constant currency and 26.5% on a reported basis.

Negative Updates

Gross Profit Margin Decline

Gross profit increased to EUR 240 million from EUR 233 million, but the gross profit margin declined to 65.2% from 68.3%, a reduction of about 3%. Management attributed the decline to a 1.3% adverse FX effect, approximately 0.5% price erosion, and a 1.3% impact from geographic and product mix, including lower U.S. sales, higher sports medicine sales, and a higher D&A ratio.

Company Guidance

Medacta confirmed its 2026 outlook for revenue growth in the range of 10%-14% and an expansion of the adjusted EBITDA margin of around 50 basis points versus prior year in constant currency; it also confirmed its midterm outlook for revenue compound annual growth rate, in constant currency, between 12% and 15%, with a gradual improvement of the adjusted EBITDA compared, versus 2025, in constant currency and subject to unforeseen events. Management said achieving the mid-portion of the guidance is possible but probably more likely to be slightly below the midline, while growing even 10%-12% in the current environment would probably be close to 3x the market.

Medacta Group SA Financial Statement Overview

Summary

Strong multi-year revenue growth with solid profitability (2025 gross margin ~64%, EBITDA margin ~27.7%, net margin ~14%). Balance sheet is sound with improved debt-to-equity (~0.58) and strong ROE (~21%). The main drag is uneven cash generation: free cash flow has been volatile and remains modest versus earnings (FCF ~19% of net income in 2025).

Income Statement

82Very Positive

Balance Sheet

76Positive

Cash Flow

63Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	706.64M	688.27M	590.58M	510.78M	437.12M	363.13M
Gross Profit	462.97M	441.40M	399.44M	347.85M	305.26M	261.25M
EBITDA	191.33M	190.07M	160.51M	134.16M	120.45M	107.12M
Net Income	77.14M	96.12M	72.89M	47.36M	46.25M	51.52M
Balance Sheet
Total Assets	1.01B	916.93M	792.18M	695.87M	584.49M	489.27M
Cash, Cash Equivalents and Short-Term Investments	36.10M	33.19M	31.59M	20.79M	32.26M	20.40M
Total Debt	321.58M	262.56M	241.21M	201.98M	170.25M	132.66M
Total Liabilities	526.20M	460.71M	412.51M	365.83M	309.83M	262.87M
Stockholders Equity	484.64M	456.22M	379.66M	330.04M	274.65M	226.40M
Cash Flow
Free Cash Flow	-1.85M	29.90M	2.45M	-7.09M	10.35M	7.57M
Operating Cash Flow	134.56M	153.65M	107.14M	75.13M	73.51M	54.06M
Investing Cash Flow	-146.01M	-137.86M	-98.87M	-80.61M	-65.11M	-52.04M
Financing Cash Flow	9.08M	-18.91M	4.33M	-10.13M	3.44M	-31.21M

Medacta Group SA Technical Analysis

Technical Analysis SentimentNegative

Last Price110.00

Price Trends

50DMA115.70Negative

100DMA124.35Negative

200DMA135.92Negative

Market Momentum

MACD-1.37Positive

RSI40.20Neutral

STOCH21.07Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:MOVE, the sentiment is Negative. The current price of 110.00 is below the 20-day moving average (MA) of 116.58, below the 50-day MA of 115.70, and below the 200-day MA of 135.92, indicating a bearish trend. The MACD of -1.37 indicates Positive momentum. The RSI at 40.20 is Neutral, neither overbought nor oversold. The STOCH value of 21.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:MOVE.

Medacta Group SA Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

CH:MOVE against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CH:YPSN	73Outperform	CHF 5.18B	25.38	28.54%	1.06%	-12.91%	-11.23%
CH:STMN	72Outperform	CHF 17.04B	45.77	―	0.94%	2.24%	-5.84%
CH:MOVE	65Neutral	CHF 2.19B	30.62	16.40%	1.00%	7.51%	-20.13%
CH:MED	62Neutral	CHF 1.47B	91.33	―	―	29.92%	―
CH:MEDX	58Neutral	CHF 431.60M	4176.00	―	0.96%	-6.64%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

CH:MOVE and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
CH:MOVE	Medacta Group Sa	110.00	-42.42	-27.83%
CH:STMN	Straumann Holding	106.65	5.87	5.83%
CH:YPSN	Ypsomed Holding AG	414.00	90.50	27.97%
CH:MEDX	medmix AG	10.44	1.77	20.37%
CH:MED	Medartis Holding AG	109.60	33.20	43.46%
CH:LEPU	Lepu Medical Technology (Beijing) Co., Ltd. Sponsored Global Depositary Receipt Repr Sh -A- Reg S	18.00	0.12	0.68%

Medacta Group SA Corporate Events

Medacta Cuts 2026 Guidance as U.S. Healthcare Market Softens

Nov 5, 2026

Medacta lowered its 2026 revenue-growth guidance to around 9% in constant currency from 10%-14%, while expecting its adjusted EBITDA margin to remain broadly in line with 2025 rather than expand by about 50 basis points. The company attributed the ch...

Medacta Delivers Above-Market H1 Growth and Expands Global Infrastructure

Sep 9, 2026

Medacta reported first-half 2026 revenue of €368 million, up 9.7% in constant currency and 7.0% in euros, outpacing the orthopedic market despite a softer U.S. environment and a spine sales channel transition.Adjusted EBITDA reached about €97 million...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026

Medacta Group SA AI Stock Analysis